Limits...
Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk patients with myocardial infarction.

Szpakowicz A, Kiliszek M, Pepinski W, Waszkiewicz E, Franaszczyk M, Skawronska M, Ploski R, Niemcunowicz-Janica A, Dobrzycki S, Opolski G, Musial WJ, Kaminski KA - PLoS ONE (2014)

Bottom Line: When all the study group was analyzed, no significant differences in mortality were found between the genotypes.However, in high-risk patients (GRACE risk score ≥ 155 points, n = 238), homozygotes associated with higher risk for ACS had significantly better 5-year survival compared to other genotypes.The genotypes associated with higher risk for ACS show a protective effect in terms of further survival (instead of a deteriorating prognosis, as reported previously).

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.

ABSTRACT

Objective: The rs10757278, rs1333049 and rs4977574 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus associated with a prevalence of acute coronary syndromes (ACS). Reports concerning their association with long-term outcome after an ACS are equivocal. The aim of our study was to investigate the association of the 9p21.3 locus with 5-year overall mortality in patients with ST-elevation myocardial infarction (STEMI).

Materials and methods: We performed a retrospective analysis of data collected prospectively in 2 independent registries of consecutive patients with STEMI (derivation and validation group). Genotyping was performed with the TaqMan method. The analyzed end-point was total mortality.

Results: The derivation group comprised 589 patients: 25.3% female (n = 149), mean age 62.4 ± 12.0 years, total 5-year mortality 16.6% (n = 98). When all the study group was analyzed, no significant differences in mortality were found between the genotypes. However, in high-risk patients (GRACE risk score ≥ 155 points, n = 238), homozygotes associated with higher risk for ACS had significantly better 5-year survival compared to other genotypes. The hazard ratio associated with the high-risk genotype (a homozygote of high risk for ACS or a heterozygote) was: HR = 2.2 (1.15-4.2) for the rs10757278 polymorphism, HR = 2.7 (95% CI 1.3-5.4) for the rs4977574 one and HR = 2.3 (1.2-4.5) for the rs1333049 one (Cox proportional hazards model). Survival analysis in the validation group (n = 365) showed a clear trend towards better prognosis in GG homozygotes of the rs10757278 SNP, which confirms our initial results (p = 0.09, log-rank test).

Conclusions: The 9p21.3 locus is associated with 5-year mortality in high-risk patients with STEMI. The genotypes associated with higher risk for ACS show a protective effect in terms of further survival (instead of a deteriorating prognosis, as reported previously). This finding, due to the very high size of the effect, could potentially be applied to clinical practice, if appropriate methods are elaborated.

Show MeSH

Related in: MedlinePlus

The rs10757278 polymorphism and long-term survival in the derivation group.No significant differences were observed between the genotypes.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4126747&req=5

pone-0104635-g001: The rs10757278 polymorphism and long-term survival in the derivation group.No significant differences were observed between the genotypes.

Mentions: A 5-year follow-up with a median of 1950 days (minimum 1824, maximum 3378 days) was performed. At the cut-off point of 1825 days (5 years) 98 patients had died (16.6%). When all the study group was analyzed, no significant differences in mortality were found between the genotypes (table 1). Figure 1 presents Kaplan-Meier surviving curves for specific genotypes of rs10757278 polymorphism and long-term mortality (p = 0.3 after adjustment for Bonferroni correction, log-rank test).


Polymorphism of 9p21.3 locus is associated with 5-year survival in high-risk patients with myocardial infarction.

Szpakowicz A, Kiliszek M, Pepinski W, Waszkiewicz E, Franaszczyk M, Skawronska M, Ploski R, Niemcunowicz-Janica A, Dobrzycki S, Opolski G, Musial WJ, Kaminski KA - PLoS ONE (2014)

The rs10757278 polymorphism and long-term survival in the derivation group.No significant differences were observed between the genotypes.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4126747&req=5

pone-0104635-g001: The rs10757278 polymorphism and long-term survival in the derivation group.No significant differences were observed between the genotypes.
Mentions: A 5-year follow-up with a median of 1950 days (minimum 1824, maximum 3378 days) was performed. At the cut-off point of 1825 days (5 years) 98 patients had died (16.6%). When all the study group was analyzed, no significant differences in mortality were found between the genotypes (table 1). Figure 1 presents Kaplan-Meier surviving curves for specific genotypes of rs10757278 polymorphism and long-term mortality (p = 0.3 after adjustment for Bonferroni correction, log-rank test).

Bottom Line: When all the study group was analyzed, no significant differences in mortality were found between the genotypes.However, in high-risk patients (GRACE risk score ≥ 155 points, n = 238), homozygotes associated with higher risk for ACS had significantly better 5-year survival compared to other genotypes.The genotypes associated with higher risk for ACS show a protective effect in terms of further survival (instead of a deteriorating prognosis, as reported previously).

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiology, Medical University of Bialystok, Bialystok, Poland.

ABSTRACT

Objective: The rs10757278, rs1333049 and rs4977574 are single nucleotide polymorphisms (SNPs) of chromosome 9p21 locus associated with a prevalence of acute coronary syndromes (ACS). Reports concerning their association with long-term outcome after an ACS are equivocal. The aim of our study was to investigate the association of the 9p21.3 locus with 5-year overall mortality in patients with ST-elevation myocardial infarction (STEMI).

Materials and methods: We performed a retrospective analysis of data collected prospectively in 2 independent registries of consecutive patients with STEMI (derivation and validation group). Genotyping was performed with the TaqMan method. The analyzed end-point was total mortality.

Results: The derivation group comprised 589 patients: 25.3% female (n = 149), mean age 62.4 ± 12.0 years, total 5-year mortality 16.6% (n = 98). When all the study group was analyzed, no significant differences in mortality were found between the genotypes. However, in high-risk patients (GRACE risk score ≥ 155 points, n = 238), homozygotes associated with higher risk for ACS had significantly better 5-year survival compared to other genotypes. The hazard ratio associated with the high-risk genotype (a homozygote of high risk for ACS or a heterozygote) was: HR = 2.2 (1.15-4.2) for the rs10757278 polymorphism, HR = 2.7 (95% CI 1.3-5.4) for the rs4977574 one and HR = 2.3 (1.2-4.5) for the rs1333049 one (Cox proportional hazards model). Survival analysis in the validation group (n = 365) showed a clear trend towards better prognosis in GG homozygotes of the rs10757278 SNP, which confirms our initial results (p = 0.09, log-rank test).

Conclusions: The 9p21.3 locus is associated with 5-year mortality in high-risk patients with STEMI. The genotypes associated with higher risk for ACS show a protective effect in terms of further survival (instead of a deteriorating prognosis, as reported previously). This finding, due to the very high size of the effect, could potentially be applied to clinical practice, if appropriate methods are elaborated.

Show MeSH
Related in: MedlinePlus